CONRAY 60 SOLUTION

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

IOTHALAMATE MEGLUMINE

Διαθέσιμο από:

LIEBEL-FLARSHEIM COMPANY LLC

Φαρμακολογική κατηγορία (ATC):

V08AA04

INN (Διεθνής Όνομα):

IOTALAMIC ACID

Δοσολογία:

600MG

Φαρμακοτεχνική μορφή:

SOLUTION

Σύνθεση:

IOTHALAMATE MEGLUMINE 600MG

Οδός χορήγησης:

INTRAVASCULAR

Μονάδες σε πακέτο:

30

Τρόπος διάθεσης:

Ethical

Θεραπευτική περιοχή:

ROENTGENOGRAPHY

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0102763001; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

2002-07-02

Αρχείο Π.Χ.Π.

_Product Monograph _
_ _
_ _
_Page 1 of 32_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
CONRAY
® 60
Iothalamate meglumine injection
Solution, 60% w/v, Intravascular
USP
Ionic Iodinated Radiographic Contrast Medium for Intravascular Use
DIN Holder:
Liebel-Flarsheim Company LLC
8800 Durant Road
Raleigh, NC 27616
USA
Importer:
Liebel-Flarsheim Canada Inc.
7500 Trans-Canada Highway
Pointe-Claire, QC, H9R 5H8
CANADA
Date of Initial Authorization:
DEC 31, 1951
Date of Revision:
AUG 23, 2022
Submission Control Number: 261648
_ _
_Product Monograph _
_ _
_< Iothalamate meglumine injection> _
_Page 2 of 32_
RECENT MAJOR LABEL CHANGES
Not applicable
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
5
1
INDICATIONS
..............................................................................................................
5
1.1
Pediatrics
..........................................................................................................
5
1.2
Geriatrics...........................................................................................................
5
2
CONTRAINDICATIONS
.................................................................................................
5
4
DOSAGE AND
ADMINISTRATION.................................................................................
6
4.1
Dosing Considerations
.......................................................................................
6
4.2
Recommended Dose and Dosage
Adjustment..................................................... 6
4.2.1
Arthrography
..............